Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Nodosin treated bladder cancer cells for transcriptome sequencing

PROVIDER: PRJNA824669 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18682973_1.fastq.gz	Fastqsanger.gz
	SRR18682973_2.fastq.gz	Fastqsanger.gz
	SRR18682974_1.fastq.gz	Fastqsanger.gz
	SRR18682974_2.fastq.gz	Fastqsanger.gz
	SRR18682975_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Homo sapiens

Project description:Nodosin treated bladder cancer cells for transcriptome sequencing

| PRJNA826421 | ENA

Homo sapiens

Project description:Nodosin treated bladder cancer cells for transcriptome sequencing

| PRJNA826422 | ENA

Project description:JorA treated bladder cancer cells for transcriptome

| PRJNA891952 | ENA

Project description:Talaroconvolutin-A treated bladder cancer cells for transcriptome sequencing

| PRJNA895115 | ENA

Genome-wide transcriptome analysis of PAK4 inhibition/knockdown in human bladder cancer cell line VMCUB1

Project description:Using multi-omic analyses, we identified PAK4 (P21 (RAC1) Activated Kinase 4) amplification and overexpression of Kinase PAK4 in a subset of bladder cancers. We confirmed the role of PAK4 in bladder cancer cell proliferation and invasion by in vitro experiments. Furthermore, our studies showed that PAK4 inhibitor is effective in curtailing bladder cancer cell growth. In order to understand the effect of PAK4 inhibition and knockdown on bladder cancer transcriptome, we performed RNA-sequencing of PAK4 siRNA transfected and PAK4 inhibitor (PF-3758309) treated bladder cancer cells (VM-CUB1). Analyses led to identification of direct targets of PAK4 in bladder cancer and associated pathways.

2020-04-20 | GSE130455 | GEO

Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles involves in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer

Project description:Proteomic characterization of extracellular vesicles derived from bladder cancer cells overexpressing GSTO1 and treated with cisplatin.

2025-02-20 | PXD049720 | JPOST Repository

Transcriptome analysis reveals anti-cancer effects of Isorhapontigenin (ISO) on human high invasive bladder cancer cells

Project description:Bladder cancer, the most common malignancy of the urinary tract, has a poor overall survival rate if the tumor becomes muscle invasive. The discovery and evaluation of new alternative medications targeting high-grade muscle invasive bladder cancer (MIBC) are of tremendous importance in reducing bladder cancer mortality. Isorhapontigenin (ISO), a stilbene derivative from Chinese herb Gnetum cleistostachyum, exhibits a strong anti-cancer effect on MIBCs. Here, we report the whole transcriptome profiling of ISO-treated human bladder cancer T24 cells. A total of 1047 differentially expressed genes (DEGs) were identified, including 596 downregulated and 451 upregulated genes. Functional annotation and pathway analysis revealed that ISO treatment induced massive changes in gene expression associated with cell movement, migration, invasion, metabolism, proliferation, and angiogenesis. Additionally, ISO treatment activated genes involved in the inflammatory response but repressed genes involved in hypoxia signaling, glycolysis, the actin cytoskeleton, and the tumor microenvironment. In summary, our whole transcriptome analysis demonstrated a shifted metabolism and altered actin cytoskeleton in ISO treated T24 cells, which subsequently contribute to tumor microenvironment remodeling that suppresses tumor growth and progression.

2024-02-14 | GSE252406 | GEO

Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells

Project description:We sought for deeper understanding of interaction mechanisms between tumor microenvironment cells, like fibroblast (FB) and mesenchymal stem cells (MSC), and bladder cancer cells to develop new cancer treatment approaches overcoming therapy resistance. To this end the bladder cancer cell lines BFTC-905 and VMCUB-1 were treated with conditioned media from FB or MSC for 72h. RNA was submitted to RNA sequencing analysis on the HiSeq 3000/4000 system (Illumina).

2023-09-04 | GSE242217 | GEO

Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells [ChIP-Seq data]

Project description:We profiled two repressive histone modifications (H3K9m3 and H3K27m3) using ChIP-Seq in normal urothelial cells and cell lines representing non-invasive and invasive tumors. Two bladder cancer cell lines (RT112 and EJ/T24 from ATCC) and normal human urothelial (NHU) cells were treated according to standard ChIP-Seq protocols using antibodies against the histone modifications H3K9m3 and H3K27m3 (from Millipore). The sequencing reads were mapped against the human genome (GRCh37/hg19).

2011-08-03 | E-GEOD-31125 | biostudies-arrayexpress

Lactylome and proteomics analyses of bladder cancer

Project description:Lactylome and proteomics analyses in bladder cancer cells treated with EPI

2025-06-10 | PXD062720 | Pride